A look at President Trump’s new pick for HHS Secretary.
This opinion piece presents the opinions of the author. It does not necessarily reflect the views of BioSpace.
President Trump favored industry experience over ideology when it came to choosing a new HHS Secretary. Alex Azar was a deputy secretary at HHS under George W. Bush before becoming president of Eli Lilly’s U.S. operations. Some have wondered if the latter background will make him less committed to lowering drug prices--a goal Trump emphasized when Tweeting the announcement--but industry insiders are, for the most part, breathing a sigh of relief. Azar has been critical of the Affordable Care Act, but has also indicated a willingness to “make it work a little better.”
Of course, that’s not the only corner office shuffling that happened this month. Read on for other key career news. -KT
Here’s a roundup of these stories and other top career news from the past month.
- It’s Official: President Trump Names Former Eli Lilly Exec HHS Secretary
- GlaxoSmithKline Poaches New CSO From Google’s Calico
- 2 Celgene Execs Jump Ship to Lead Immunomedics
- Merck Plots 950-Job R&D Hub in London
- Teva Expected to Fire Up to 1,700 Workers in Israel, U.S.
Read More From Karl Thiel:
Are We Reaching the Biotech Singularity?
